证券之星消息，12月10日动物保健板块较上一交易日下跌0.31%，*ST绿康领跌。当日上证指数报收于 3900.5，下跌0.23%。深证成指报收于13316.42，上涨0.29%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1398.26万元，游资资金净流出1834.36万元，散 户资金净流入3232.62万元。动物保健板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 14.53 | 1.18% | 39.53万 | | 5.60亿 | | 300119 | 瑞普生物 | 19.24 | 0.79% | 2.69万 | 5155.97万 | | | 002141 | 贤丰控股 | 3.82 | 0.53% | 17.77万 | 6770.24万 | | | 920275 ...

证券之星消息，12月8日动物保健板块较上一交易日上涨1.81%，生物股份领涨。当日上证指数报收于 3924.08，上涨0.54%。深证成指报收于13329.99，上涨1.39%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 14.39 | 7.39% | 71.75万 | | 10.14亿 | | 600195 | 中牧股份 | 8.09 | 1.25% | 18.04万 | | 1.46亿 | | 920970 | 大禹生物 | 7.88 | 0.90% | ● 1.01万 | | 802.74万 | | 920729 | 永顺生物 | 8.85 | 0.80% | 6781.98 | | 602.31万 | | 300119 | 瑞普生物 | 19.37 | 0.73% | 3.19万 | | 6169.99万 | | 002688 | 金河生物 | 6.16 | 0.65% | 13.17万 | | 8088. ...

Core Viewpoint - The animal health sector experienced a decline of 0.48% on December 1, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.65% and the Shenzhen Component Index increasing by 1.25% [1][2]. Market Performance - The closing price of *ST Lvkang was 39.35, reflecting a decrease of 3.41% with a trading volume of 30,400 shares and a transaction value of 122 million yuan [2]. - Other notable stocks in the animal health sector included: - Dayu Biological: Closing price 8.26, up 2.10% [1] - Haili Biological: Closing price 6.86, up 1.03% [1] - Qihua Biological: Closing price 15.85, up 0.51% [1] - Repu Biological: Closing price 19.83, down 0.10% [1][2]. Capital Flow - The animal health sector saw a net outflow of 29.57 million yuan from institutional investors, while retail investors contributed a net inflow of 3.27 million yuan [2][3]. - Specific stock capital flows included: - Jinhai Biological: Net inflow from institutional investors of 3.13 million yuan [3]. - Haili Biological: Net inflow from institutional investors of 2.06 million yuan [3]. - Repu Biological: Net inflow from retail investors of 2.81 million yuan [3].

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on November 24, with *ST Lvkang leading the drop [1][2] Market Performance - The Shanghai Composite Index closed at 3836.77, up 0.05% - The Shenzhen Component Index closed at 12585.08, up 0.37% [1] Individual Stock Performance - Notable gainers in the animal health sector included: - Shenlian Biological (688098) with a closing price of 9.57, up 2.57% on a trading volume of 55,100 shares and a turnover of 52.32 million yuan - Yongshun Biological (920729) at 8.95, up 1.59% with a trading volume of 15,900 shares and a turnover of 14.22 million yuan - Xianfeng Holdings (002141) at 3.98, up 1.53% with a trading volume of 694,200 shares and a turnover of 275 million yuan [1] Capital Flow Analysis - The animal health sector saw a net outflow of 35.49 million yuan from institutional investors, while retail investors contributed a net inflow of 31.36 million yuan [2][3] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [3] Stock-Specific Capital Flow - Key stocks with significant capital flow include: - Dayu Biological (920970) with a net inflow of 1.55 million yuan from institutional investors - Pulaike (603566) with a net inflow of 0.99 million yuan from institutional investors - Shenlian Biological (688098) faced a net outflow of 2.88 million yuan from institutional investors [3]

Core Viewpoint - The company Jinhe Biological has developed a synthetic astaxanthin product with strong antioxidant capabilities, applicable in various sectors including health food, aquaculture, feed, pharmaceuticals, and cosmetics [2] Company Summary - Jinhe Biological's astaxanthin product is the first synthetic biology product resulting from a strategic partnership with Shanghai Jiao Tong University School of Life Sciences and Technology [2] - The astaxanthin is produced as a metabolic byproduct of red yeast during fermentation, offering a higher yield and lower cost compared to natural extraction methods [2] - The company has established an annual production capacity of 3,000 tons of astaxanthin, with the feed additive product already receiving approval and currently in the market promotion phase [2]

Core Viewpoint - The company, Jinhe Biology, has developed astaxanthin products with strong antioxidant capabilities, applicable in various fields such as health food, aquaculture, feed, pharmaceuticals, and cosmetics [2]. Group 1: Product Application and Market Response - Astaxanthin products can be utilized in health food, aquaculture, feed, pharmaceuticals, and cosmetics due to their strong antioxidant properties [2]. - The company has initiated a strategic partnership with Shanghai Jiao Tong University School of Life Sciences and Technology to develop its first synthetic biology product, astaxanthin [2]. - The astaxanthin produced is a metabolite from red yeast during fermentation, which has a similar left-handed structure to naturally extracted astaxanthin from red algae, but with higher yield and lower cost compared to natural extraction methods [2]. Group 2: Production Capacity and Market Promotion - The company has established an annual production capacity of 3,000 tons for astaxanthin [2]. - The feed additive product derived from red yeast has received product approval and is currently in the market promotion phase [2].

Core Viewpoint - The company has developed astaxanthin products with strong antioxidant capabilities, applicable in various fields such as health food, aquaculture, feed, pharmaceuticals, and cosmetics [2]. Group 1: Product Applications - Astaxanthin can be utilized in health food, aquaculture, feed, pharmaceuticals, and cosmetics due to its strong antioxidant properties [2]. - The company's astaxanthin product is the first synthetic biology product developed in collaboration with Shanghai Jiao Tong University [2]. Group 2: Production and Market Status - The company has established an annual production capacity of 3,000 tons of astaxanthin [2]. - The feed additive derived from red yeast has received product approval and is currently in the market promotion phase [2].

Core Viewpoint - The company, Jinhe Biology, is leveraging its astaxanthin product, which has strong antioxidant properties, for applications in health food, aquaculture, feed, pharmaceuticals, and cosmetics [1] Group 1: Product Development - The astaxanthin product is the first synthetic biology product developed in collaboration with Shanghai Jiao Tong University School of Life Sciences [1] - The product is a metabolic byproduct of red yeast during fermentation, with a structure similar to natural astaxanthin extracted from red algae [1] - The synthetic method offers higher yield and lower cost compared to natural extraction methods [1] Group 2: Production Capacity - The company has established an annual production capacity of 3,000 tons for astaxanthin [1] - The feed additive product derived from red yeast has received product approval and is currently in the market promotion phase [1]

Core Viewpoint - The animal health sector experienced a slight decline of 0.31% on November 19, with Xianfeng Holdings leading the losses, while the Shanghai Composite Index rose by 0.18% to close at 3946.74 [1]. Group 1: Market Performance - The animal health sector's individual stock performance varied, with notable gainers including Qudongli (up 3.98% to 10.71) and ST Lvkang (up 3.80% to 46.40) [1]. - Conversely, several stocks faced declines, such as Jinhai Biological (down 0.96% to 6.19) and Shunlian Biological (down 1.08% to 10.12) [1][2]. Group 2: Trading Volume and Capital Flow - The total trading volume for the animal health sector was significant, with Qudongli achieving a volume of 34,000 hands and a transaction value of approximately 35.9 million yuan [1]. - The sector saw a net outflow of 49.13 million yuan from institutional investors, while retail investors contributed a net inflow of 548.09 million yuan [2]. Group 3: Individual Stock Capital Flow - Among individual stocks, Shengong Holdings experienced a net outflow of 31.56 million yuan from retail investors, while Biotech Holdings saw a net inflow of 555.72 million yuan from retail investors [3]. - The stock with the highest net inflow from retail investors was Biotech Holdings, with 555.72 million yuan, while the largest net outflow was from Yongshun Biological, totaling 408.61 million yuan [3].